Abstracts tagged "Outcome measures"

Abstract Number: 0523 • ACR Convergence 2023
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Fabian Proft¹, Désirée van der Heijde², Xenofon Baraliakos³, Joerg Ermann⁴, Carmen Fleurinck⁵, Ute Massow⁶, Natasha De Peyrecave⁷, Vanessa Taieb⁸, Astrid van Tubergen⁹ and Victoria Navarro-Compán¹⁰, ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Colombes, France, ⁹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, ¹⁰Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic rheumatic disease which requires optimal management and disease control. Patients (pts) can experience loss of response in the…
Abstract Number: 1055 • ACR Convergence 2023
Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort
Vanissa Savarimuthu¹, Alexandra Ladouceur², Oliver Terry¹, Janet Roberts³, Janet Pope⁴, Thomas Appleton⁴, Sabrina Hoa⁵, Aurore Fifi-Mah⁶, Nancy Maltez⁷, Alexandra Saltman⁸, Megan Himmel⁸, Ines Colmegna⁹, Lindsay Cho¹⁰, Emma Schmidt¹⁰, Claudie Berger¹¹, Thomas Barnetche¹², Lourdes Gonzalez Arreola¹³, Carrie Ye¹⁴, Shahin Jamal¹⁵ and Marie Hudson¹⁶, ¹McGill University, Montreal, QC, Canada, ²Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Montreal, Brossard, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷The Ottawa Hospital, Ottawa, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹⁰University of British Columbia, Vancouver, BC, Canada, ¹¹RI-MUHC, Montreal, QC, Canada, ¹²Bordeaux University Hospital, Bordeaux, France, ¹³Arthritis Research Canada, Vancouver, BC, Canada, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶McGill University, Montréal, QC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. A drawback of ICI therapy is their off-target effects known as immune-related adverse events…
Abstract Number: 1323 • ACR Convergence 2023
Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1
Peter C. Taylor¹, Yoshiya Tanaka², Emily Aiello³, Thomas P.A. Debray⁴, Chris Watson⁵, Kristina Harris⁶ and Gerd Burmester⁷, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Real-world Analytics, Cytel, Toronto, ON, Canada, ⁴Biostatistics, Galapagos NV, Mechelen, Belgium, ⁵Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: FINCH 1 (NCT02889796) was a Phase 3 randomized controlled trial evaluating filgotinib (FIL) in patients with rheumatoid arthritis and an inadequate response to methotrexate…
Abstract Number: 1623 • ACR Convergence 2023
Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement, Antibody Pattern and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Kathryn Torok³, Ozgur Kasapcopur⁴, Amra Adrovic⁵, Brian Feldman⁶, FLAVIO SZTAJNBOK⁷, Maria Teresa TErreri⁸, Ana Sakamoto⁹, Sindhu Johnson¹⁰, Jordi Anton¹¹, Valda Stanevica¹², Raju Khubchandani¹³, Dieneke Schonenberg-Meinema¹⁴, Eslam Al-Abadi¹⁵, Ekaterina Alexeeva¹⁶, Maria Katsikas¹⁷, Sujata Sawhney¹⁸, Vanessa Smith¹⁹, Simone Appenzeller²⁰, Tadey Avcin²¹, Mikhail Kostik²², Thomas Lehman²³, Hana Malcova²⁴, Edoardo Marrani²⁵, Clare Pain²⁶, Natalia Vasquez-Canizares²⁷, Patricia Costa Reis²⁸, Mahesh Janarthanan²⁹, Maria Jose Santos³⁰, Sima Abu Alsaoud³¹, Christina Battagliotti³², Lillemor Berntson³³, blanca e r bica³⁴, Juergen Brunner³⁵, Daniela Kaiser³⁶, Dragana Lazarevic³⁷, Kirsten Minden³⁸, Farzana Nuruzzaman³⁹, Siri Opsahl Hetlevik⁴⁰, Yosef Uziel⁴¹ and Nicola Helmus⁴², ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Istanbul University - Cerrahpasa, Istanbul, Turkey, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷UFRJ/UERJ, São Paulo, Brazil, ⁸UNIFESP, São Paulo, Brazil, ⁹Federal University of São Paulo (UNIFESP), São Paulo, Brazil, ¹⁰Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ¹¹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹²Children's Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹³SRCC Childrens Hospital, Mumbai, India, ¹⁴Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁵Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, ¹⁶Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ¹⁷Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ¹⁸Sir Ganga Ram Hospital, Uttar Pradesh, India, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰UNICAMP, Campinas, Brazil, ²¹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²²Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²³Hospital for Special Surgery, New York, NY, ²⁴Motol University Hospital, Prague, Czech Republic, ²⁵University of Florence, Firenze, Italy, ²⁶Alder Hey NHS Trust, Liverpool, United Kingdom, ²⁷Children’s Hospital at Montefiore, Bronx, NY, ²⁸Hospital de Santa Maria, Lisbon, Portugal, ²⁹SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, India, ³⁰Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³¹Caritas baby Hospital, East Jerusalem, Israel, ³²Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ³³Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ³⁴Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ³⁵Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ³⁶Children's Hospital Lucerne, Lucerne, Switzerland, ³⁷Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, ³⁸Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ³⁹Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁰Oslo University Hospital, Oslo, Norway, ⁴¹Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁴²Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. In adult patients there are significant differences between…
Abstract Number: 1980 • ACR Convergence 2023
Movement Evoked Pain as an Outcome Measure in Patients with Knee Osteoarthritis
Leila Bagherzadeh¹, Schnitzer Thomas², Santiago Espinosa-Salas¹ and Joana Barroso³, ¹Northwestern Physical Medicine and Rehabilitation Department, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Anesthesiology; Feinberg School of Medicine, Chicago, IL
Background/Purpose: Pain, being one of the most crucial symptoms associated with knee OA, serves as a significant outcome measure for the increasing number of studies…
Abstract Number: 2282 • ACR Convergence 2023
Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19
Arthur Mageau¹, Christel Gerardin², Kankoe Sallah², Jean-Francois Timsit¹, Thomas Papo¹ and Karim Sacre¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France
Background/Purpose: The SARS-CoV2 pandemic reopened the unresolved question of whether and how a viral infection can trigger flares of immune-mediated inflammatory diseases such as systemic…
Abstract Number: 2538 • ACR Convergence 2023
Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study
Pin-Chia Huang¹, Debby Cheng², Megan H Noe³, Jui-En Lo⁴, Steven T Chen³ and Kevin Sheng-Kai Ma⁵, ¹Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ²Harvard Medical School, Boston, MA, ³Department of Dermatology, Massachusetts General Hospital, Boston, MA, ⁴Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis and type 2 diabetes mellitus (T2D) may share common underlying pathophysiology, in which the pathogenesis of psoriasis is mediated by NOD-like receptor family…
Abstract Number: 0246 • ACR Convergence 2023
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
Herbert Baraf¹, Alan Kivitz², Sheri Rhodes³, Sheldon Leung⁴, Olu Folarin⁴, Tania Gonzalez-Rivera⁵, Joanna Sobierska⁵, Jacquie Christie⁵, Anand Patel⁶, Wesley DeHaan⁴, Rehan Azeem⁴ and Peter Traber⁷, ¹The Center for Rheumatology and Bone Research, George Washington University, Rheumatology, Bethesda, MD, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Atlanta, GA, ⁴Selecta Biosciences, Inc., Watertown, MA, ⁵Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden, ⁶Pioneer Research Solutions, Houston, TX, ⁷Selecta Biosciences, Gladwyne, PA
Background/Purpose: In patients with refractory gout, the inability to maintain serum uric acid (sUA) levels < 6 mg/dL leads to severe clinical manifestations for which…
Abstract Number: 0590 • ACR Convergence 2023
Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus
Jui-En Lo¹, Pin-Chia Huang², George Tsokos³, Vasileios Kyttaris⁴, Karen Costenbader⁵ and Kevin Sheng-Kai Ma², ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴BIDMC, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i), originally approved as oral hypoglycemic agents for type 2 diabetes (T2D), have been shown to reduce progression to end-stage…
Abstract Number: 1065 • ACR Convergence 2023
Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs
Ogheneyoma Akpoviroro¹, Nathan Sausers², Oghenetejiro Akpoviroro³, Queeneth Uwandu¹, Myriam Castagne⁴, Elga Rodrigues⁴, Lefulesele Khoalone¹, sara Humayun¹ and Jameson Woodard¹, ¹Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA, ²Pennsylvania State University, State College, PA, ³Mater Dei Hospital, Msida, Malta, ⁴Boston University, Boston, MA
Background/Purpose: Describe patients(pts) hospitalized with COVID-19C(C19) who were on disease modifying antirheumatic drugs (DMARDs) before admission(BA); assess if clinical outcomes differed from pts without BA…
Abstract Number: 1368 • ACR Convergence 2023
Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Benjamin A Fisher¹, Linda Stone², Jessica Marvel³, Pushpendra Goswami⁴, Monia Steenackers⁴, Gayle Kenney⁴, Chiara Perella⁵, Wolfgang Hueber⁴, Chloe Howse⁶, Elizabeth Gargon⁶, Aishwarya Chohan⁶, Megan Mayhew⁶ and Nicola Williamson⁶, ¹University of Birmingham, Birmingham, United Kingdom, ²The British Sjogren’s Syndrome Association, Birmingham, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Riehen, Switzerland, ⁶Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom
Background/Purpose: Sjögren's is a heterogenous chronic auto-immune disease, characterized by excessive dryness of the eyes and mouth, as well as systemic complications which can significantly…
Abstract Number: 1624 • ACR Convergence 2023
Racial Disparities Impact Achieving LLDAS and Glucocorticoid Use in Pediatric Lupus: A CARRA Registry Study
William Soulsby¹, Rebecca Olveda¹, Jie He², Laura Berbert², Edie Weller², Kamil Barbour³, Kurt Greenlund³, Laura Schanberg⁴, Emily von scheven¹, Aimee Hersh⁵, Mary Beth Son⁶, Joyce Chang² and Andrea Knight⁷, ¹University of California San Francisco, San Francisco, CA, ²Boston Children's Hospital, Boston, MA, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴Duke University School of Medicine, Durham, NC, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Immunology, Boston Children's Hospital, Boston, MA, ⁷The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Social determinants of health (SDoH) contribute to disparate outcomes in both adult and pediatric systemic lupus erythematosus (pSLE), including length of hospitalization, mortality, and…
Abstract Number: 1988 • ACR Convergence 2023
Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis
Andrew Spitzer¹, Helena Rodbard², Sheikh Usman Iqbal³, Masato Nakazawa³, Mary DiGiorgi³ and Roy Winston³, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Endocrine and Metabolic Consultants, Rockville, MD, ³Pacira BioSciences, Inc., Tampa, FL
Background/Purpose: Intraarticular (IA) corticosteroids are generally considered safe and effective to treat osteoarthritis of the knee (OAK) but may cause hyperglycemia that may last for…
Abstract Number: 2288 • ACR Convergence 2023
Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set
Wils Nielsen¹, Vibeke Strand², Lee Simon³, Maya Desai⁴, Ioannis Parodis⁵, Alfred Kim⁶, Daniel Wallace⁷, Yashaar Chaichian⁸, Sandra Navarra⁹, Cynthia Aranow¹⁰, Meggan MacKay¹⁰, Kimberly Trotter¹¹, Oshrat Tayer-Shifman¹², Ali Duarte-Garcia¹³, Lai-Shan Tam¹⁴, Manuel Ugarte-Gil¹⁵, Guillermo Pons-Estel¹⁶, John Reynolds¹⁷, Mandana Nikpour¹⁸, Danae Papachristos¹⁹, Alberta Hoi²⁰, Alison Hendry²¹, Juanita Romero-Diaz²², Rosalind Ramsey-Goldman²³, Hanan Alrayes²⁴, Ibrahim Almaghlouth²⁵, Aarabi Thayaparan²⁶, Carolina Munoz-Grajales²⁷, Aaron Howe²⁸, Behdin Nowrouzi-Kia²⁸, Melanie Anderson²⁹, Dennisse Bonilla²⁹, Julian Thumboo³⁰, Marta Mosca³¹, Martin Aringer³², Sindhu Johnson³³, Aaron Drucker³⁴, Eric Morand³⁵, Ian Bruce³⁶ and Zahi Touma²⁸, ¹University of Toronto, Markham, ON, Canada, ²Stanford University, Portola Valley, CA, ³SDG LLC, West Newton, MA, ⁴OCAD University, Toronto, ON, Canada, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸Stanford University, San Mateo, CA, ⁹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹University of Chicago, Chicago, IL, ¹²Meir Medical Center, Raanana, Israel, ¹³Mayo Clinic, Rochester, MN, ¹⁴The Chinese University of Hong Kong, New Territories, China, ¹⁵Universidad Cientifica del Sur, Lima, Peru, ¹⁶RELESSAR, Rosario, Argentina, ¹⁷University of Birmingham, Birmingham, United Kingdom, ¹⁸The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ¹⁹Mater Hospital, Brisbane, Australia, ²⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ²¹Te Whatu Ora, Counties Manukau District, Middlemore Hospital, Auckland, New Zealand, ²²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²³Northwestern University, Chicago, IL, ²⁴Riyadh Military - Prince Soltan Military Medical City ( PSMMC ) - Olaya, Riyadh, Saudi Arabia, ²⁵King Saud University, Riyadh, Saudi Arabia, ²⁶Schroeder Arthritis Institute, Krembil Research Institute, Markham, ON, Canada, ²⁷UHN/TWH, Toronto, ON, Canada, ²⁸University of Toronto, Toronto, ON, Canada, ²⁹University Health Network, Toronto, ON, Canada, ³⁰Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ³¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ³²Faculty of Medicine TU Dresden, Dresden, Germany, ³³Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ³⁴Women's College Hospital, Toronto, ON, Canada, ³⁵Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³⁶University of Manchester, Manchester, United Kingdom
Background/Purpose: We established the OMERACT SLE Working Group in 2021 which includes over 150 members representing over 25 countries and 5 continents to develop a…
Abstract Number: 2551 • ACR Convergence 2023
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Ioannis Parodis¹, Julius Lindblom¹, Roger A. Levy², Margherita Zen³, Nursen Cetrez¹, Alvaro Gomez⁴, Shereen Oon⁵, Christine Henning⁶, Munther Khamashta⁷, Holly A. Quasny⁸, Deven Chauhan⁹, Anca Askanase¹⁰, Ronald van Vollenhoven¹¹ and Mandana Nikpour¹², ¹Karolinska Institutet, Stockholm, Sweden, ²GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ³University of Padua, Division of Rheumatology, Department of Medicine, Padua, Italy, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ⁶GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁷GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁸GlaxoSmithKline, Research & Development, Durham, NC, ⁹GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].